BALTIMORE, July 27 /PRNewswire/ -- Alba Therapeutics announced today the hiring of Stuart D. Sedlack as Senior Vice President, Corporate Development. Mr. Sedlack will be responsible for commercial affairs, including business development, market planning and strategic planning.
“We are very pleased that Stuart is joining Alba,” said Blake Paterson, M.D., Alba’s Chief Executive Officer. “Mr. Sedlack is an accomplished business development executive with a significant track record in strategic collaborations, joint ventures and financings having spent the last eighteen years in the pharmaceutical and banking industry. His leadership and experience will be critical to Alba as we build the foundation of our commercialization strategy and consider opportunities partnering Alba’s strategic assets.”
Prior to joining Alba, Mr. Sedlack was the Global Head of Negotiations for the Infectious Diseases Transplantation & Immunology business unit of Novartis Pharma AG, based in Basel, Switzerland, where he negotiated and closed a number of transactions helping to establish Novartis with a leading Infectious Diseases pipeline. From 1997 through 2003 Mr. Sedlack was Vice President, Corporate Development with Elan Corporation, PLC, where he was responsible for strategic licensing, investments, portfolio management activities, and restructurings.
Previously, Mr. Sedlack served as Director at the University of Maryland Medical System’s technology licensing office from 1993 to 1997. Mr. Sedlack began his career in banking and finance in 1988 working for ABN AMRO Bank, N.V. and MNC International Bank and specialized in international trade finance. Throughout his career Mr. Sedlack has served on the Board of Directors for several public and private biotechnology companies.
Mr. Sedlack holds a Bachelor of Arts degree in Economics from the University of Richmond and a Master of Business Administration degree from Babson College.
About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics based on the zonulin pathway. Alba’s lead molecule, AT-1001, is targeted toward the treatment of celiac disease and other autoimmune illnesses.
Media Contact: Heather Bakalyar of Alba Therapeutics Corporation, +1-410-319-0780 ext. 110.
Alba Therapeutics Corporation
CONTACT: Heather Bakalyar of Alba Therapeutics Corporation,+1-410-319-0780 ext. 110
Web site: http://www.albatherapeutics.com/
